Therapix Biosciences (Israel) Probability of Target Price Finishing Over Current Price

    TRPX -- Israel Stock  

    null 33.70  0.70  2.12%

    Therapix Biosciences probability of target price tool provides mechanism to make assumptions about upside and downside potential of Therapix Biosciences Ltd performance during a given time horizon utilizing its historical volatility. Please specify Therapix Biosciences time horizon, a valid symbol (red box) and a target price (blue box) you would like Therapix Biosciences odds to be computed. Also please take a look at World Market Map.
    Horizon     30 Days    Login   to change
    Symbol:
    Refresh Odds

    Therapix Biosciences Target Price Odds to finish over

    Current PriceHorizonTarget PriceOdds to move above current price in 30 days
     33.70 30 days 33.70  ABOUT 26.79%
    Based on normal probability distribution, the odds of Therapix Biosciences to move above current price in 30 days from now is about 26.79% (This Therapix Biosciences Ltd probability density function shows the probability of Therapix Biosciences Stock to fall within a particular range of prices over 30 days) .
    Assuming 30 trading days horizon, Therapix Biosciences Ltd has beta of -1.4461 . This entails as returns on its benchmark rise, returns on holding Therapix Biosciences Ltd are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, Therapix Biosciences is expected to outperform its benchmark. Additionally Therapix Biosciences Ltd has a negative alpha implying that the risk taken by holding this equity is not justified. The company is significantly underperforming DOW
     Therapix Biosciences Price Density 
          Price 
    α
    Alpha over DOW
    =0.13
    β
    Beta against DOW=1.45
    σ
    Overall volatility
    =14.56
    Ir
    Information ratio =0.0031

    Therapix Biosciences Alerts

    Therapix Biosciences Alerts and Suggestions

    Therapix Biosciences is not yet fully synchronised with the market data
    Therapix Biosciences has high likelihood to experience some financial distress in the next 2 years
    The company reported revenue of . Net Loss for the year was (7.66M).
    THERAPIX BIO has accumulated about 7.51M in cash with (6.01M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.04.
    Also please take a look at World Market Map. Please also try Balance Of Power module to check stock momentum by analyzing balance of power indicator and other technical ratios.
    Search macroaxis.com